The United States retains its lead over China in biotechnology, but that lead is narrowing, according to the latest Biotech Scorecard from the Special Competitive Studies Project (SCSP), a nonprofit and nonpartisan initiative aimed at strengthening America's long-term competitiveness in artificial intelligence. The report warns that China could overtake the U.S. by 2030, buoyed by two decades of deliberate national strategy that is now producing results.
SCSP's Tech Scorecard methodology evaluates five elements: Innovation Leadership, Market Ecosystem, Talent Pipeline, Industrial Capacity, and National Leverage. The United States leads in Innovation Leadership, Market Ecosystem, and Talent Pipeline, while China appears ahead in Industrial Capacity and National Leverage. This split underscores a critical vulnerability: America's advantage rests largely on past research investments and a capital market that rewards top performers, rather than on a coordinated national strategy for commercialization and scale-up.
The report focuses on the biopharmaceuticals sector to illustrate China's acceleration. Most U.S. government funding for biotechnology goes to basic research, with limited urgency in expanding support for commercializing drug products. "Approval timelines for drugs entering clinical trials and going to domestic markets are driven by government policy, and can help accelerate, or slow down, the pipeline of innovation," the SCSP authors emphasize. In contrast, China actively supports biotech startups through preferential taxation, below-market lending, and direct subsidies, helping them acquire capital, build pilot capacity, scale production, and reach markets without waiting for a definitive return on investment. The U.S. tends to leave this aspect to the private sector.
The implications are significant as artificial intelligence transforms drug discovery. As AI allows scientists to predict molecular activity, the expensive early stages of discovery will likely decrease, shifting competitive advantage to testing, manufacturing, and commercializing promising drug candidates. "Whether the United States retains its edge depends both on model quality and how quickly it can move a computationally generated candidate through trials, approval, and manufacture before a competitor improves on it," according to the report. This means that without faster regulatory processes and stronger government support for scaling and manufacturing, the U.S. could lose its lead even if it maintains superiority in innovation and talent.
The scorecard serves as a wake-up call for policymakers and industry leaders. It highlights that biotechnology leadership is not determined by a single factor but by supply chains, manufacturing capacity, data holdings, and regulatory speed. China's holistic approach, combining state financing, industrial policy, and regulatory flexibility, poses a direct challenge to the U.S. model. To read the full report and learn more, visit scsp.ai. The analysis was released by (NewsUSA).
